Drugging an undruggable pocket on KRAS.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
06 08 2019
Historique:
pubmed: 25 7 2019
medline: 27 3 2020
entrez: 24 7 2019
Statut: ppublish

Résumé

The 3 human RAS genes, KRAS, NRAS, and HRAS, encode 4 different RAS proteins which belong to the protein family of small GTPases that function as binary molecular switches involved in cell signaling. Activating mutations in RAS are among the most common oncogenic drivers in human cancers, with KRAS being the most frequently mutated oncogene. Although KRAS is an excellent drug discovery target for many cancers, and despite decades of research, no therapeutic agent directly targeting RAS has been clinically approved. Using structure-based drug design, we have discovered BI-2852 (1), a KRAS inhibitor that binds with nanomolar affinity to a pocket, thus far perceived to be "undruggable," between switch I and II on RAS; 1 is mechanistically distinct from covalent KRAS

Identifiants

pubmed: 31332011
pii: 1904529116
doi: 10.1073/pnas.1904529116
pmc: PMC6689897
doi:

Substances chimiques

KRAS protein, human 0
Pharmaceutical Preparations 0
Guanosine Triphosphate 86-01-1
Proto-Oncogene Proteins p21(ras) EC 3.6.5.2

Banques de données

PDB
['6GJ5', '6GJ6', '6GJ7', '6GJ8']

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

15823-15829

Subventions

Organisme : NCI NIH HHS
ID : P50 CA095103
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2019 the Author(s). Published by PNAS.

Déclaration de conflit d'intérêts

Conflict of interest statement: D.K., M.G., A.M., L.J.M., A.Z., M.M., A.G., D.C., S.F., T. Gerstberger, T. Gmashitz, P.G., D.H., W.H., J.H., J.K.-O., P.K., S.K., M.K., R.K., L.L., F.M., S.M.-M., C.P., J.R., C.S., Y.S., K.S., R.S., A.S., B.S., G.S., B.W., M.Z., M.P., and D.B.M. were employees of Boehringer Ingelheim at the time of this work.

Références

J Med Chem. 2017 Jul 13;60(13):5791-5799
pubmed: 28590130
J Am Chem Soc. 2001 Jun 27;123(25):6108-17
pubmed: 11414845
Angew Chem Int Ed Engl. 2012 Jun 18;51(25):6140-3
pubmed: 22566140
J Chem Inf Comput Sci. 2004 Nov-Dec;44(6):2157-66
pubmed: 15554686
Cell. 2003 Mar 7;112(5):685-95
pubmed: 12628188
Cancer Res. 2012 May 15;72(10):2457-67
pubmed: 22589270
Oncogene. 2008 May 8;27(21):2961-8
pubmed: 18059342
Nat Rev Drug Discov. 2007 Mar;6(3):211-9
pubmed: 17290284
Cancer Cell. 2015 Sep 14;28(3):370-83
pubmed: 26343582
Methods Mol Biol. 2009;517:133-44
pubmed: 19378012
Science. 2001 Nov 9;294(5545):1299-304
pubmed: 11701921
Mol Cancer Res. 2015 Sep;13(9):1325-35
pubmed: 26037647
Nat Commun. 2018 Aug 9;9(1):3169
pubmed: 30093669
Nat Rev Drug Discov. 2016 Nov;15(11):771-785
pubmed: 27469033
Science. 1990 Feb 23;247(4945):939-45
pubmed: 2406906
Science. 1997 Jul 18;277(5324):333-8
pubmed: 9219684
Cell. 2018 Jan 25;172(3):578-589.e17
pubmed: 29373830
J Synchrotron Radiat. 2008 May;15(Pt 3):227-30
pubmed: 18421145
Curr Opin Chem Biol. 2007 Oct;11(5):485-93
pubmed: 17851109
Curr Protoc Cell Biol. 2009 Jun;Chapter 14:Unit 14.9
pubmed: 19499504
Nature. 2014 Jul 31;511(7511):543-50
pubmed: 25079552
Proc Natl Acad Sci U S A. 2019 Feb 12;116(7):2545-2550
pubmed: 30683716
J Clin Oncol. 2012 Jul 10;30(20):2522-9
pubmed: 22614978
Proc Natl Acad Sci U S A. 2012 Apr 3;109(14):5299-304
pubmed: 22431598
Oncogene. 2016 Dec 15;35(50):6389-6402
pubmed: 27157612
Blood. 2006 May 15;107(10):3847-53
pubmed: 16434492
Sci STKE. 2004 Sep 07;2004(250):RE13
pubmed: 15367757
Nature. 1999 Nov 18;402(6759):313-20
pubmed: 10580505
Science. 1996 Nov 29;274(5292):1531-4
pubmed: 8929414
J Mol Recognit. 1999 Jan-Feb;12(1):3-18
pubmed: 10398392
Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5426-30
pubmed: 8202502
ChemMedChem. 2008 Sep;3(9):1371-6
pubmed: 18576452
Nucleic Acids Res. 2018 Jul 2;46(W1):W363-W367
pubmed: 29860391
Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):4944-9
pubmed: 11320243
Semin Cell Dev Biol. 2016 Oct;58:70-8
pubmed: 27297135
Anal Biochem. 2018 May 1;548:44-52
pubmed: 29444450
Cancer. 2000 Feb 1;88(3):518-23
pubmed: 10649241
Nature. 2012 Nov 15;491(7424):399-405
pubmed: 23103869
Structure. 2015 Mar 3;23(3):505-516
pubmed: 25684575
Cancer Cell. 2012 Nov 13;22(5):668-82
pubmed: 23153539
J Biol Chem. 2001 Jul 20;276(29):27629-37
pubmed: 11333268
Nature. 1998 Jul 23;394(6691):337-43
pubmed: 9690470
Methods Mol Biol. 2008;439:327-37
pubmed: 18370113
Pathol Res Pract. 2009;205(12):858-62
pubmed: 19679400
Oncogene. 2005 Aug 4;24(33):5218-25
pubmed: 15897885
EMBO J. 1998 Aug 3;17(15):4313-27
pubmed: 9687500
Nat Struct Biol. 1997 Aug;4(8):609-15
pubmed: 9253406

Auteurs

Dirk Kessler (D)

Discovery Research, Boehringer Ingelheim Regional Center Vienna GmbH & Co KG, 1120 Vienna, Austria.

Michael Gmachl (M)

Discovery Research, Boehringer Ingelheim Regional Center Vienna GmbH & Co KG, 1120 Vienna, Austria.

Andreas Mantoulidis (A)

Discovery Research, Boehringer Ingelheim Regional Center Vienna GmbH & Co KG, 1120 Vienna, Austria.

Laetitia J Martin (LJ)

Discovery Research, Boehringer Ingelheim Regional Center Vienna GmbH & Co KG, 1120 Vienna, Austria.

Andreas Zoephel (A)

Discovery Research, Boehringer Ingelheim Regional Center Vienna GmbH & Co KG, 1120 Vienna, Austria.

Moriz Mayer (M)

Discovery Research, Boehringer Ingelheim Regional Center Vienna GmbH & Co KG, 1120 Vienna, Austria.

Andreas Gollner (A)

Discovery Research, Boehringer Ingelheim Regional Center Vienna GmbH & Co KG, 1120 Vienna, Austria.

David Covini (D)

Discovery Research, Boehringer Ingelheim Regional Center Vienna GmbH & Co KG, 1120 Vienna, Austria.

Silke Fischer (S)

Discovery Research, Boehringer Ingelheim Regional Center Vienna GmbH & Co KG, 1120 Vienna, Austria.

Thomas Gerstberger (T)

Discovery Research, Boehringer Ingelheim Regional Center Vienna GmbH & Co KG, 1120 Vienna, Austria.

Teresa Gmaschitz (T)

Discovery Research, Boehringer Ingelheim Regional Center Vienna GmbH & Co KG, 1120 Vienna, Austria.

Craig Goodwin (C)

Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37235.

Peter Greb (P)

Discovery Research, Boehringer Ingelheim Regional Center Vienna GmbH & Co KG, 1120 Vienna, Austria.

Daniela Häring (D)

Discovery Research, Boehringer Ingelheim Regional Center Vienna GmbH & Co KG, 1120 Vienna, Austria.

Wolfgang Hela (W)

Discovery Research, Boehringer Ingelheim Regional Center Vienna GmbH & Co KG, 1120 Vienna, Austria.

Johann Hoffmann (J)

Discovery Research, Boehringer Ingelheim Regional Center Vienna GmbH & Co KG, 1120 Vienna, Austria.

Jale Karolyi-Oezguer (J)

Discovery Research, Boehringer Ingelheim Regional Center Vienna GmbH & Co KG, 1120 Vienna, Austria.

Petr Knesl (P)

Discovery Research, Boehringer Ingelheim Regional Center Vienna GmbH & Co KG, 1120 Vienna, Austria.

Stefan Kornigg (S)

Discovery Research, Boehringer Ingelheim Regional Center Vienna GmbH & Co KG, 1120 Vienna, Austria.

Manfred Koegl (M)

Discovery Research, Boehringer Ingelheim Regional Center Vienna GmbH & Co KG, 1120 Vienna, Austria.

Roland Kousek (R)

Discovery Research, Boehringer Ingelheim Regional Center Vienna GmbH & Co KG, 1120 Vienna, Austria.

Lyne Lamarre (L)

Discovery Research, Boehringer Ingelheim Regional Center Vienna GmbH & Co KG, 1120 Vienna, Austria.

Franziska Moser (F)

Discovery Research, Boehringer Ingelheim Pharma GmbH & Co KG, D-88397 Biberach an der Riss, Germany.

Silvia Munico-Martinez (S)

Discovery Research, Boehringer Ingelheim Regional Center Vienna GmbH & Co KG, 1120 Vienna, Austria.

Christoph Peinsipp (C)

Discovery Research, Boehringer Ingelheim Regional Center Vienna GmbH & Co KG, 1120 Vienna, Austria.

Jason Phan (J)

Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37235.

Jörg Rinnenthal (J)

Discovery Research, Boehringer Ingelheim Regional Center Vienna GmbH & Co KG, 1120 Vienna, Austria.

Jiqing Sai (J)

Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37235.

Christian Salamon (C)

Discovery Research, Boehringer Ingelheim Regional Center Vienna GmbH & Co KG, 1120 Vienna, Austria.

Yvonne Scherbantin (Y)

Discovery Research, Boehringer Ingelheim Regional Center Vienna GmbH & Co KG, 1120 Vienna, Austria.

Katharina Schipany (K)

Discovery Research, Boehringer Ingelheim Regional Center Vienna GmbH & Co KG, 1120 Vienna, Austria.

Renate Schnitzer (R)

Discovery Research, Boehringer Ingelheim Regional Center Vienna GmbH & Co KG, 1120 Vienna, Austria.

Andreas Schrenk (A)

Discovery Research, Boehringer Ingelheim Regional Center Vienna GmbH & Co KG, 1120 Vienna, Austria.

Bernadette Sharps (B)

Discovery Research, Boehringer Ingelheim Regional Center Vienna GmbH & Co KG, 1120 Vienna, Austria.

Gabriella Siszler (G)

Discovery Research, Boehringer Ingelheim Regional Center Vienna GmbH & Co KG, 1120 Vienna, Austria.

Qi Sun (Q)

Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37235.

Alex Waterson (A)

Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37235.
Department of Chemistry, Vanderbilt University, Nashville, TN 37235.

Bernhard Wolkerstorfer (B)

Discovery Research, Boehringer Ingelheim Regional Center Vienna GmbH & Co KG, 1120 Vienna, Austria.

Markus Zeeb (M)

Discovery Research, Boehringer Ingelheim Pharma GmbH & Co KG, D-88397 Biberach an der Riss, Germany.

Mark Pearson (M)

Discovery Research, Boehringer Ingelheim Regional Center Vienna GmbH & Co KG, 1120 Vienna, Austria.

Stephen W Fesik (SW)

Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37235.
Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37235.
Department of Chemistry, Vanderbilt University, Nashville, TN 37235.

Darryl B McConnell (DB)

Discovery Research, Boehringer Ingelheim Regional Center Vienna GmbH & Co KG, 1120 Vienna, Austria; darryl.mcconnell@boehringer-ingelheim.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH